Welcome to our dedicated page for Korsana Biosciences SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Korsana Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Korsana Biosciences's regulatory disclosures and financial reporting.
Cyclerion Therapeutics, Inc. (CYCN) reported that Chief Financial Officer Rhonda M. Chicko was granted an option to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The grant, reported with a transaction date of 08/07/2025, is under the 2019 Equity Incentive Plan. Of the 25,000 shares, 8,750 are immediately exercisable and 16,250 vest in monthly installments beginning August 31, 2025 and ending February 28, 2028, subject to continued service. The option expires August 6, 2035, and the reporting person is shown as the direct beneficial owner of the 25,000 option shares following the transaction.